Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian share markets remain in green
Wed, 22 May 11:30 am

Indian share markets have continued on a firm note during the previous two hours of trade. IT and healthcare are leading the pack of winners while realty and auto are facing the maximum selling pressures.

The BSE-Sensex is up by 68 points and NSE-Nifty is up by 17 points. BSE Mid Cap index is trading up by 0.3% while BSE Small Cap index is trading up by 0.2%. The rupee is trading at 55.44 to the US dollar.

Indian Pharma shares are trading on a mixed note with Dr. Reddy's and Sun Pharma leading the gains while Divis Laboratories and Wockhardt Ltd are leading the losses. According to a leading financial news daily, the Health Mininstry in India has decided to initiate a probe on Ranbaxy Laboratories following the company's legal trouble in the US. The Drugs Controller General of India (DCGI) has been ordered to examine all the dossiers and drug applications on the basis of which approvals were granted to Ranbaxy in the past, a ministry source in know of the developments said. The future course of action would be decided after DCGI's report, expected to come within a month. All the officials spoken to said Ranbaxy could face severe penalties under the Drugs and Cosmetics Act if it was found guilty of violation of any provision under Indian law. According to the health ministry source, the drug regulator will initially study the US court's order and the report of the US Food and Drug Administration (FDA) and examine the period under their review, primarily pre-2005 in the Indian context. Ranbaxy's share is trading down by 1.5%.

Auto shares are trading on a mixed note with Maharashtra Scooters and Tata Motors leading the gains while TVS Motors and Force Motors are leading the losses. According to a leading financial news medium, the country's largest car maker - Maruti Suzuki's Swift Dzire has emerged as the second-highest sold car in India after Alto. The entity has sold 19,446 units of the compact sedan in April. With the increase in demand for compact sedans, the company hopes that Dzire will maintain its speed in the days ahead. Dzire sales have increased dramatically after the company went for a full model revamp last year and launched a new sub-four-metre model in February. The smaller size has allowed Dzire to halve its tax outgo, making it eligible for a lower tax bracket of 12%, and consequently passing on the benefit to customers. Maruti's share is trading up by 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian share markets remain in green". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks